Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Metabasis Therapeutics Inc
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Metabasis Therapeutics Inc since year 2005.
Table 2 shows the detailed insider transactions of Metabasis Therapeutics Inc since 2005.
The reporting company's ticker symbol is MBRX. The reporting company's CIK number is 1053221.
The total value of stock buying since 2005 is $24,858,897.
The total value of stock sales since 2005 is $428,418.
The total value of stock option exercises since 2005 is $22,019.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2008-11-19||Laikind Paul K (Chief Executive Officer)||Buy||4,700||.63||2,956|
|2008-11-18||Laikind Paul K (Chief Executive Officer)||Buy||1,300||.54||698|
|2008-04-16||Rosch Thomas L (10% Owner)||Buy||990,816||2.34||2,318,509|
|2008-04-16||Galakatos Nicholas (10% Owner)||Buy||71,866||2.34||168,166|
|2008-04-16||Oronsky Arnold L (Director)||Buy||990,816||2.34||2,318,509|
|2008-04-16||Evnin Luke (Director)||Buy||71,866||2.34||168,166|
|2008-04-16||Hale David F||Buy||10,000||2.34||23,400|
|2008-04-16||Credit Suisse/ (10% Owner)||Buy||196,633||2.34||460,121|
|2007-06-19||Beck John W (Chief Financial Officer)||Sale||3,400||8.05||27,376|
|2007-06-01||Beck John W (Chief Financial Officer)||Sale||10,035||8.00||80,330|
|2007-05-22||Beck John W (Chief Financial Officer)||Sale||300||8.00||2,400|
|2007-04-25||Beck John W (Chief Financial Officer)||Sale||3,300||8.13||26,829|
|2007-04-24||Baracchini Edgardo Jr (Sr. VP of Business Development)||Sale||4,300||8.21||35,303|
|2007-04-10||Beck John W (Chief Financial Officer)||Sale||6,172||8.00||49,376|
|2007-04-09||Beck John W (Chief Financial Officer)||Sale||1,828||8.00||14,624|
|2007-02-26||Beck John W (Chief Financial Officer)||Sale||3,300||8.00||26,400|
|2007-02-26||Baracchini Edgardo Jr (Sr. VP of Business Development)||Sale||700||8.00||5,600|
|2006-12-05||Beck John W (Chief Financial Officer)||Sale||9,000||8.00||72,000|
|2006-11-27||Beck John W (CFO)||Sale||500||8.01||4,005|
|2006-11-08||Beck John W (Sr. VP, Finance & CFO)||Sale||9,000||8.00||72,000|
|2006-11-03||Credit Suisse/ (10% Owner)||Buy||527,000||7.16||3,775,955|
|2006-06-26||Baracchini Edgardo Jr (Sr. VP, Business Development)||Sale||500||8.35||4,175|
|2006-06-07||Gschwend Heinz W (Director)||Option Ex||11,864||1.86||22,019|
|2006-05-22||Cash Harvey B (10% Owner)||Buy||39,836||8.02||319,644|
|2006-05-19||Cash Harvey B (10% Owner)||Buy||5,000||8.10||40,500|
|2006-05-18||Cash Harvey B (10% Owner)||Buy||700||8.10||5,670|
|2006-05-16||Cash Harvey B (10% Owner)||Buy||4,464||8.00||35,703|
|2006-03-01||Beck John W (Chief Financial Officer)||Sale||1,000||8.00||8,000|
|2005-09-30||Rosch Thomas L (10% Owner)||Buy||426,621||5.86||2,499,999|
|2005-09-30||Galakatos Nicholas (Director)||Buy||699,659||5.86||4,100,001|
|2005-09-30||Oronsky Arnold L (Director)||Buy||426,621||5.86||2,499,999|
|2005-09-30||Evnin Luke (10% Owner)||Buy||699,659||5.86||4,100,001|
|2005-09-30||Credit Suisse First Boston/ (Other)||Buy||341,297||5.86||2,000,000|
|2005-09-07||Gschwend Heinz W (Director)||Buy||5,000||4.18||20,900|
Insider trading activities including stock purchases, stock sales, and option exercises of MBRX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Metabasis Therapeutics Inc (symbol MBRX, CIK number 1053221) see the Securities and Exchange Commission (SEC) website.